(News Bulletin 247) – Portzamparc maintains its recommendation to ‘buy’ on Theradiag, pointing out that the manufacturer of in vitro diagnostic systems came close to profitability in the first half.
In a study released on Monday, the analyst points out that the company’s net result, which stands at -56,000 euros over the first six months of the year, would have been positive up to +10,000 euros in the event of credit. constant research tax.
According to Portzamparc, this ‘near-profitable’ first half suggests a positive result in the second half thanks to the steady growth of the company’s turnover, which according to him provides the fuel necessary to achieve this point of equilibrium (‘breakeven’).
‘Some adjustments on the side of operating expenses will probably be necessary to switch significantly in profitability’, however, estimates the design office in its note.
Portzamparc says it has adjusted its price target on the title, which it reduces from 2.4 to 2.3 euros, recalling that its scenario so far anticipated profitability from the first half of the 2022 financial year.
Copyright (c) 2022 News Bulletin 247. All rights reserved.